___

• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 2003;101:4701-4707.
• Talpaz DM. STI-571 in chronic myelogenous leukemia. British Journal of Haematology, 2002; 119:15-24.
• Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Cancer, 2003; 98:1905-1911.
• Rowley JD. A new consistent abnormality in chronic myelogenous leukemia identified quinacrine fluorescence and giemsa staining. Nature, 1973; 243:290-293.
• Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science, 1960; 132: 1947.
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev, 2002; 1:493- 502.
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med, 2003; 348:994-1004.
• Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Seminars in Hematology, 2003; 40:4-10.
• Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia negative cells during imatinib treatment of Philadelphia positive chronic myeloid leukemia. Leukemia, 2004; 18:1340-1346.
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukamia. Nature Reviews, Cancer, 2005; 5: 172-183.
• Bocchia M, Gentili S, Abruzesse E, et al. Effect of a multipeptide vaccine associated with imatinib or in- terferon in patients with chronic myelogenous leukemia and persistent residual disease: a multicentre observational trial. Lancet, 2005; 365:657-662.
• Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Seminars in Hematology, 2003; 40:11-14.
• Feldman E, Najfeld V, Schuster M, Roboz G, Chadborn A, Silver RT. The emergence of Ph-, trisomy 8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental Hematology, 2003; 31:702-707.
• Tothova E, Kafkova A, Fricova M, et al. Imatinib mesylate in Philadelphia chromosome positive chronic phase myeloid leukemia after failure of interferon alpha. Neoplasma, 2005; 52:63-67.
• Gadzicki D, Neuhoff NV, Steinemann D, et al. BCR- ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genetics and Cytogenetics, 2005; 159:164-167.
• O’Dwyer, Gatter KM, Loriaux M, et al.
• Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia, 2003; 17:481-487.
• Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 2005; 103: 1659-1669.
• Czepulkowski B. Analyzing Chromosomes. First Published 2001, Bios Scientific.
• Mitelman F. An International System for Cytogenetic Nomenclature , ISCN, 1995, Karger, Basel.
• Kantarjian H, Talpaz M, O’brien S, et al. Survival benefit with imatinib mesylate yherapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience. Cancer, 2005; 103:2099-2108.
• Tunca Y, Guran Ş. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases. Experimental Hematology, 2005; 33:151.
• Bernardeschi P, Fiorentini G, Rossi S, et al. Trisomy 8 in Philadelphia negative cells during imatinib therapy. American Journal of Hematology, 2004; 77:88-89.